Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

• Main Authors: G. Carlino (Author), M. Fornaro (Author), L. Santo (Author), R. Bucci (Author), A. Semeraro (Author), L. Quarta (Author), F. D'Onofrio (Author), A. Marsico (Author), C. Zuccaro (Author), P.C. Falappone (Author), D. Mazzotta (Author), F.P. Cantatore (Author), M. Muratore (Author), F. Iannone (Author)
• Format: Book
• Published: PAGEPress Publications, 2019-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We performed a retrospective analysis to evaluate the survival on first line biologic drug of rheumatoid arthritis (RA) patients with potential occult HBV infection (pOBI). We analysed longitudinal data of 486 consecutive RA patients starting a first biological drug in a time frame from 1st January...